<DOC>
	<DOCNO>NCT01765114</DOCNO>
	<brief_summary>The aim study therefore investigate efficacy PEG-formulation reduce frequency duration genital herpes recurrence , assess safety tolerability investigate effect shedding .</brief_summary>
	<brief_title>A Study Investigate Efficacy , Safety Tolerability PEG Patients With Genital Herpes</brief_title>
	<detailed_description />
	<mesh_term>Herpes Genitalis</mesh_term>
	<criteria>Informed Consent 18 65 year Positive HSV1 and/or 2 ( determine serology test course study ) Initial infection &gt; 1 year ago ≥ 6 recurrence last year ( year prior recent prophylactic therapy ) ≥ 2 recurrence sixmonth baseline period Known suspect allergy intolerability PEG Prophylactic antiviral drug , virostatic agent , cytostatics , immunomodulatory drug steroid within less 14 day prior baseline period , plan take drug trial Pregnancy and/or breastfeed History malignant disease ( describe chapter 7.2 ) Known suspected noncompliance study protocol Participation another investigational drug study last 30 day prior baseline period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>